AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.
| Revenue (Most Recent Fiscal Year) | $31.02M |
| Net Income (Most Recent Fiscal Year) | $-57.83M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.91 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.83 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -179.67% |
| Net Margin (Trailing 12 Months) | -177.79% |
| Return on Equity (Trailing 12 Months) | -44.60% |
| Return on Assets (Trailing 12 Months) | -22.25% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.53 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.53 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.29 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.21 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.58 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.58 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 100.41M |
| Free Float | 95.79M |
| Market Capitalization | $192.79M |
| Average Volume (Last 20 Days) | 0.11M |
| Beta (Past 60 Months) | 1.57 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 51.36% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |